Charles Schwab Investment Management Inc. Increases Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Charles Schwab Investment Management Inc. grew its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 2.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 462,309 shares of the biopharmaceutical company’s stock after acquiring an additional 10,116 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sage Therapeutics were worth $2,510,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Ieq Capital LLC acquired a new stake in Sage Therapeutics during the 4th quarter worth $57,000. US Bancorp DE boosted its stake in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 2,268 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Sage Therapeutics during the fourth quarter worth about $91,000. SG Americas Securities LLC increased its position in shares of Sage Therapeutics by 57.7% during the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 8,228 shares in the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of Sage Therapeutics by 56.3% in the 3rd quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 6,618 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Analyst Upgrades and Downgrades

SAGE has been the topic of several research analyst reports. Piper Sandler cut their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Scotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research report on Wednesday, February 12th. HC Wainwright reissued a “neutral” rating and set a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Finally, Bank of America assumed coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.81.

Sage Therapeutics Price Performance

SAGE opened at $8.28 on Friday. Sage Therapeutics, Inc. has a 12 month low of $4.62 and a 12 month high of $18.76. The stock has a market capitalization of $509.06 million, a P/E ratio of -1.26 and a beta of 0.82. The business has a 50 day simple moving average of $7.48 and a 200-day simple moving average of $6.74.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Research analysts anticipate that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.